Results 21 to 30 of about 687 (125)

USE OF DIMETHYL FUMARATE IN THE TREATMENT OF MULTIPLE SCLEROSIS: CLINICAL AND ECONOMIC ANALYSIS

Неврология, нейропсихиатрия, психосоматика, 2016
The paper presents a review of an update on the comparative pharmacoeconomic analysis of using dimethyl fumarate in the treatment of multiple sclerosis (MS) in European countries. A pharmacoeconomic evaluation was made to study the use of first-line oral
V. R. Mkrtchyan, L. V. Brylev, I. A. Shpak, A. M. Sergeev   +3 more
doaj   +1 more source

A Sensitization-Free Dimethyl Fumarate Prodrug, Isosorbide Di-(Methyl Fumarate), Provides a Topical Treatment Candidate for Psoriasis

JID Innovations, 2021
Dimethyl fumarate (DMF) is an effective oral treatment for psoriasis administered in Europe for nearly 60 years. However, its potential has been limited by contact dermatitis that prohibits topical application.
Krzysztof Bojanowski, Collins U. Ibeji, Parvesh Singh, William R. Swindell, Ratan K. Chaudhuri   +4 more
doaj   +1 more source

Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up

Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2017
Background Dimethyl fumarate and fingolimod are oral disease-modifying therapies approved to treat relapsing multiple sclerosis. Prior observational studies and our previous 12-month investigation showed comparable clinical efficacy.
Carrie M Hersh, Thomas E Love, Anasua Bandyopadhyay, Samuel Cohn, Claire Hara-Cleaver, Robert A Bermel, Robert J Fox, Jeffrey A Cohen, Daniel Ontaneda   +8 more
doaj   +1 more source

Effect of dimethyl fumarate on lymphocyte subsets in patients with relapsing multiple sclerosis

Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2020
Background In patients treated with dimethyl fumarate, absolute lymphocyte count decline typically occurs during the first year and then plateaus; early drops have been associated with the development of severe prolonged lymphopenia.
Guy Buckle, Daniel Bandari, Jeffrey Greenstein, Mark Gudesblatt, Bhupendra Khatri, Mariko Kita, Pavle Repovic, Emily Riser, Bianca Weinstock-Guttman, Ben Thrower, Sherrill Loring, Katherine Riester, Nick Everage, Claudia Prada, Irene Koulinska, Monica Mann   +15 more
doaj   +1 more source

Dimethyl fumarate as a safe and effective therapy for recalcitrant psoriasis in comorbid patients

Dermatology Reports, 2021
Psoriasis is a chronic condition for which multiple therapies are currently available. In particular, in cases of moderate-severe psoriasis, traditional systemic drugs or the new biological drugs can be administered.
Martina Burlando, Mattia Fabio Molle, Emanuele Cozzani, Aurora Parodi   +3 more
doaj   +1 more source

Effects of dimethyl fumarate on neuroprotection and immunomodulation

Journal of Neuroinflammation, 2012
Background Neuronal degeneration in multiple sclerosis has been linked to oxidative stress. Dimethyl fumarate is a promising novel oral therapeutic option shown to reduce disease activity and progression in patients with relapsing-remitting multiple ...
Albrecht Philipp, Bouchachia Imane, Goebels Norbert, Henke Nadine, Hofstetter Harald H, Issberner Andrea, Kovacs Zsuzsa, Lewerenz Jan, Lisak Dmitrij, Maher Pamela, Mausberg Anne-Kathrin, Quasthoff Kim, Zimmermann Corinna, Hartung Hans-Peter, Methner Axel   +14 more
doaj   +1 more source

Calming the (Cytokine) Storm: Dimethyl Fumarate as a Therapeutic Candidate for COVID-19

Pharmaceuticals, 2020
COVID-19 has rapidly spread worldwide and incidences of hospitalisation from respiratory distress are significant. While a vaccine is in the pipeline, there is urgency for therapeutic options to address the immune dysregulation, hyperinflammation and ...
Cara A. Timpani, Emma Rybalka
doaj   +1 more source

A Prospective Study of Individuals at Risk of Multiple Sclerosis Informs the Design of Primary Prevention Studies

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective In multiple sclerosis, the optimal time for deploying a therapeutic intervention is before the central nervous system is damaged; given the success of trials treating the earliest stage of MS, the radiologically isolated syndrome, developing primary prevention strategies is an important next challenge.
Amy W. Laitinen, Ceren Tozlu, Tina Roostaei, Fatoumata Diallo, Kaho Onomichi, Jiyeon Son, Zongqi Xia, Philip L. De Jager   +7 more
wiley   +1 more source

Paramagnetic Rim Lesions Are Associated With Trans‐Synaptic Degeneration of the Visual Pathway in Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives Retrograde trans‐synaptic degeneration (rTSD) from posterior visual pathway lesions in multiple sclerosis (MS) is characterized by hemi‐macular ganglion cell‐inner plexiform layer (GCIPL) thinning and contralateral visual field loss.
Abdul Jaber Tayem, Angel Liu, Sargis Manukyan, Mustafa Subhi, Elaina Luskin, Bryan Quah, Sreekanth Madhusoodhanan Nair, Arzu C. Has Silemek, Gabriela Zabala, Yujie Cui, Laura Locke, Paula Barreras, Marwa Kaisey, Vinicius Calsavara, Daniel S. Reich, Nancy L. Sicotte, Pascal Sati, Omar Al‐Louzi   +17 more
wiley   +1 more source

Gut microbiota composition during a 12-week intervention with delayed-release dimethyl fumarate in multiple sclerosis – a pilot trial

Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019
Introduction Patients with multiple sclerosis may have a distinct gut microbiota profile. Delayed-release dimethyl fumarate is an orally administered drug for relapsing–remitting multiple sclerosis, which has been associated with gastrointestinal side ...
C Storm-Larsen, K-M Myhr, E Farbu, R Midgard, K Nyquist, L Broch, P Berg-Hansen, A Buness, K Holm, T Ueland, L-E Fallang, E Burum-Auensen, JR Hov, T Holmøy   +13 more
doaj   +1 more source